Date
Friday, July 31, 2026
Time
9:45 AM - 11:00 AM (MDT)
Name
Pipeline to Progress: Angelman Syndrome Therapeutics & Clinical Trial Updates
Description
Hear directly from leading pharmaceutical and biotech partners—Ultragenyx, Ionis Pharmaceuticals, Oak Hill Bio, Lundbeck, and MavriX Bio—as they share updates on current and emerging therapies for Angelman syndrome. This session offers a unique opportunity to learn about the latest progress in clinical trials and what it may mean for the future of our community.
Location Name
Aurora A, C, D
Speakers
Candice Junge, Ionis Pharmaceuticals
Kim Goodspeed, Ultragenyx
Brenda Vincenzi, Oak Hill Bio
David Chapman, Lundbeck
Jennifer Panagoulias, Mavrix Bio
Kim Goodspeed, Ultragenyx
Brenda Vincenzi, Oak Hill Bio
David Chapman, Lundbeck
Jennifer Panagoulias, Mavrix Bio
Moderator(s)
Becky Burdine
Session Type
General Session